# US 2012/0252829 A1 · Tivozanib and capecitabine combination therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252829 A1
- Document ID: US20120252829A1
- Status: Published application
- Kind: A1
- Application number: 13/436,021
- Filed: 2012-03-30
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Inventors: Jie Lin; Jeno Gyuris; Feng Jiang; Guangmu Li; Xiaojian Sun
- Web page: https://patentgrep.com/patent/US20120252829A1

## CPC

- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating a tumor in a subject using a combination of tivozanib and capecitabine is disclosed.

## Claims

### Claim 1

A method of treating a tumor in a subject, comprising co-administering to the patient: (a) tivozanib and (b) capecitabine.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 3 (depends on 1)

The method of claim 1, wherein tivozanib is dosed at 0.5-2.0 mg daily.

### Claim 4 (depends on 1)

The method of claim 1, wherein tivozanib is dosed at 1.5 mg daily.

### Claim 5 (depends on 1)

The method of claim 1, wherein capecitabine is dosed at 400-2000 mg/m2 twice daily.

### Claim 6 (depends on 1)

The method of claim 1, wherein capecitabine is dosed at 800 mg/m2 twice daily.

### Claim 7 (depends on 1)

The method of claim 1, wherein capecitabine is dosed at 1250 mg/m2 twice daily.

### Claim 8 (depends on 1)

The method of claim 1, wherein capecitabine is dosed at 2000 mg/m2 twice daily.

### Claim 9 (depends on 1)

The method of claim 1, wherein tivozanib is administered orally one dose per day for three weeks, followed by one week without tivozanib administration.

### Claim 10 (depends on 1)

The method of claim 1, wherein capecitabine is administered orally on a repeating schedule of one dose twice daily for two weeks, followed by one week without capecitabine administration.

### Claim 11 (depends on 1)

The method of claim 1, wherein capecitabine is administered orally on a repeating schedule of one dose twice daily for one week, followed by one week without capecitabine administration.

### Claim 12 (depends on 1)

The method of claim 1, wherein the tumor is a breast tumor.

### Claim 13 (depends on 1)

The method of claim 1, wherein the tumor is a colorectal tumor.

### Claim 14 (depends on 1)

The method of claim 1, wherein tivozanib is N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]-phenyl}-N′-(5-methyl-3-isoxazolyl)urea monohydrochloric acid salt monohydrate.
